DePuy Synthes launched the CONDUIT Interbody Platform with EIT Cellular Titanium Technology. The portfolio includes 3D-printed titanium interbody implants with 80% porosity to mimic the 50% to 90% porosity of natural bone.
This is the first series of devices to launch from Johnson & Johnson’s 2018 acquisition of Emerging Implant Technologies (EIT). CONDUIT Implants and DePuy Synthes’ ACIS ProTi 360° Anterior Cervical Interbody System Hyperlordotic Cages are expected to strengthen the company’s interbody cage lineup and contribute to a revenue boost for its spine segment.
CONDUIT implants feature nanoscale surface roughness to support osteoblast adhesion and a modulus of elasticity similar to cancellous bone.
DePuy Synthes’ CONDUIT Interbody Platform with EIT Cellular Titanium Technology
DePuy Synthes launched the CONDUIT Interbody Platform with EIT Cellular Titanium Technology. The portfolio includes 3D-printed titanium interbody implants with 80% porosity to mimic the 50% to 90% porosity of natural bone.
This is the first series of devices to launch from Johnson & Johnson's 2018 acquisition of Emerging Implant...
DePuy Synthes launched the CONDUIT Interbody Platform with EIT Cellular Titanium Technology. The portfolio includes 3D-printed titanium interbody implants with 80% porosity to mimic the 50% to 90% porosity of natural bone.
This is the first series of devices to launch from Johnson & Johnson’s 2018 acquisition of Emerging Implant Technologies (EIT). CONDUIT Implants and DePuy Synthes’ ACIS ProTi 360° Anterior Cervical Interbody System Hyperlordotic Cages are expected to strengthen the company’s interbody cage lineup and contribute to a revenue boost for its spine segment.
CONDUIT implants feature nanoscale surface roughness to support osteoblast adhesion and a modulus of elasticity similar to cancellous bone.
DePuy Synthes’ CONDUIT Interbody Platform with EIT Cellular Titanium Technology
Copy to clipboard 
